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Probiotics are deﬁned as live organisms, which confer beneﬁts to the host. Their eﬃciency was demonstrated for the treatment
of gastrointestinal disorders, respiratory infections, and allergic symptoms, but their use is mostly limited to bacterial and viral
diseases. During the last decade, probiotics as means for the control of parasite infections were reported covering mainly intestinal
diseases but also some nongut infections, that are all of human and veterinary importance. In most cases, evidence for a beneﬁcial
eﬀect was obtained by studies using animal models. In a few cases, cellular interactions between probiotics and pathogens or
relevant host cells were also investigated using in vitro culture systems. However, molecular mechanisms mediating the beneﬁcial
eﬀects are as yet poorly understood. These studies indicate that probiotics might indeed provide a strain-speciﬁc protection
against parasites, probably through multiple mechanisms. But more unravelling studies are needed to justify probiotic utilisation
in therapeutics.
1.Introduction
Probiotics have been deﬁned by WHO as “live organisms
which when administered in adequate amounts confer
a health beneﬁt to the host” (http://www.who.int/
foodsafety/publications/fs management/probiotics2/en/).
Importantly, a general probiotic statement on a genus or a
species cannot be established, as two closely related strains
can induce inverse eﬀects. Therefore, a probiotic must
always be fully characterised at a strain level [1]. A good
probioticstrainshouldconferabeneﬁcialproperty(immune
stimulation,protectionagainstpathogens,metabolism,etc.),
be nonpathogenic, resistant to low pH and acids, thereby
persisting in the intestine, and able to adhere to the gut
epithelium [2]. About 50 strains corresponding to 26 species
fulﬁl these criteria. Most probiotic organisms are gram
positive bacteria, isolated from the human gut microﬂora
or various dairy products such as curd, lassi, and kulﬁ.
However, probiotic beneﬁcial eﬀects have been more often
demonstrated in model animals than by direct clinical
evidences and depend largely on the dose ingested. Dose of
at least ﬁve billion colony forming units per day for at least
5d a y si sr e c o m m e n d e d[ 2]. This minimum dose takes into
account the survival capacity of the ingested probiotics in
the gastrointestinal tract, where they are in competition with
the resident bacteria [3]. Three main beneﬁts are reported
(Figure 1).
Modulation of the intestinal environment, by probiotics
having the capacity to control the proliferation of surround-
ing microorganisms and/or by competition for the occu-
pancy of a common biotope (e.g., access to nutriments) [2].
For example, iron is a limiting nutriment: it is essential for
most bacteria, and probiotics can compete for its availability.
Lactobacillus can render iron unavailable for pathogenic
microorganisms, either by binding ferric hydroxide on its
surface [4] or by secreting siderophores that chelate and
transport iron [3]. Some probiotics are also able to inﬂuence
the composition and equilibrium of the gut microﬂora (For
review, see [5]). For example, probiotic therapy using a
mixture of probiotics (VSL#3) was shown to increase the
totalnumberofintestinalbacteriaandtorestorethediversity
of the bacterial microbiota in patients [6]. Finally, probiotics
can also control their biotic environment through regulation
of intestinal motility and mucus secretion [2].
Secretion of active molecules (e.g. bacteriocins, antibi-
otics, free fatty acids, hydrogen peroxide) that can control2 Journal of Parasitology Research
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Figure 1: Schematic representation of the diﬀerent routes by which probiotics may control a pathogen. (1) Probiotics can modulate
their physicochemical environment (nutrients, mucus, receptors availability on epithelial cells, pH, tight junctions, and peristaltism).
(2) Probiotics can produce biologically active molecules such as bacteriocins, antibiotics, or oxygen peroxide that possess antimicrobial
properties. (3) Probiotics can induce immune modulation, either through interaction with dendritic cells that can, in turn, modulate the
diﬀerentiationofna¨ ıveTcellsintoTh1,Th2,orTreglymphocytes,leadingtodiﬀerentcytokineinductionand/orthroughahumoralimmune
response via IgA producing cells and their secretory IgA (sIgA).
growth and/or survival of surrounding microorganisms.
Bacteriocins are secreted peptides or proteins that generally
kill closely related bacteria by permeabilizing their mem-
branes or by interfering with essential enzymes (For review,
see [5]). Many of them are produced by Lactobacillus probi-
otic strains (lactacin B, lactacin F, nisin, etc.). Lactobacillus
reuteri produces reuterin (3-hydroxypropionaldehyde), a
broad-spectrum antibiotic, active against bacteria, yeast,
fungi, protozoa, and viruses [7]. By lowering the local
intestinal pH with lactic acid, probiotics can also modify the
growth of acid-sensitive organisms [5].
Modulation of immunity, by stimulating the host im-
mune response to a variety of pathogens. In the gut, probi-
otics interact with the epithelial cells, Peyer’s patches M cells,
and immune cells. These interactions result in an increase
in the number of IgA producing cells accompanied by
production of IgM and secretory IgA which are particularly
important in mucosal immunity, contributing to the barrier
against pathogenic organisms [8, 9]. In addition, probiotics
can also aﬀect dendritic cells, which are responsible for col-
lection of antigens from gut and their presentation to na¨ ıve T
cells, leading to their diﬀerentiation to T-helper (Th1, Th2)
orT-regulatorylymphocytes.Probioticmoleculesimplicated
in dendritic cell induction are poorly characterized, one
exception being the S layer protein A of L. acidophilus
NCFM that regulates maturation of dendritic cells and T
cell functions [10]. Probiotics have also been shown to
modulate cytokine release (TNF-α IFN-γ, IL-10, IL-12)
[11]. These cytokines play a central role in maintaining the
delicate balance between necessary and excessive defence
mechanisms. For instance, polysaccharide A, synthesized by
Bacillus fragilis NCTC 9343, protects against experimental
colitis through an adequate induction of IL-10 production
[12].
In conclusion, probiotics can kill or inhibit pathogens by
strain-speciﬁcmechanismsrelyingoncompetition,molecule
secretion, and/or immune induction. Most of the described
interactions imply a prokaryotic pathogen that colonizes the
same gut compartment. Recently, several studies have inves-
tigated whether probiotics could control the proliferation of
eukaryotic pathogens, either in the gut as the probiotic, or
in a diﬀerent compartment (Figure 2, Table 1). This concept
is supported by recent studies showing that gut commensal
microﬂoracanplayacriticalroleinthecompletionofthelifeJournal of Parasitology Research 3
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Figure 2: Schematic representation of the diﬀerent eukaryotic pathogens (gut or nongut pathogens) for which probiotics have been tested.
Not to scale. Approximate sizes: adult Ascaris up to 30cm; Cryptosporidium oocyst 4μm; Eimeria oocyst 10μm; Giardia cyst 15μm; adult
Toxocara up to 20cm; adult Trichinella 3mm. Babesia 5μm; Plasmodium 7μm, adult Schistosoma 16mm, and Trypanosoma trypomastigote
12μm. Spo.: Sporozoite; Tro.: Trophozoite; Mer.: Merozoite; Cer.: Cercae; Ama.: Amastigote; Try.: Trypomastigote.
cycle of the intestinal parasitic nematode Trichuris muris and
in the modulation of the host immune response [13]andcan
also provide indirect protective immunostimulation against
the nongut parasite, Toxoplasma gondii [14]. In the following
chapters, we will report the recent ﬁndings concerning the
eﬀects of probiotics on several parasites as illustrated in
Table 1 and propose future directions to help to standardize
probiotic tests on eukaryotic pathogens.
2. Cryptosporidium
Cryptosporidium is an intestinal pathogen belonging to the
Alveolata group that can cause devastating gastrointestinal
infection in immunosuppressed humans. In the environ-
ment, Cryptosporidium is found as oocyst, the infective form,
in water. After ingestion, the oocysts travel through the
gut lumen to the small intestine, where they release the
motile sporozoites that adhere and invade the epithelial
gastrointestinal cells. The sporozoites focally disrupt the
microvilli and penetrate the host cells to establish their
intracellularniche,wheretheyremaininanextracytoplasmic
vacuole. After parasite replication and evasion, oocysts
are generated and excreted in the faeces (for a review,
see [15]) (Figure 2). Intestinal epithelial cells, infected by
Cryptosporidium parvum,s h o wi m p a i r e dN a + and H2O
absorption as well as enhanced Cl− secretion, leading to
diarrhea. Abnormalities in the barrier properties of the
intestinal epithelium, caused in part by the disruption
of intercellular junctional complexes, contribute also to
diarrhea. Despite a real risk of waterborne outbreaks of
cryptosporidiosis, there is no completely eﬃcient ther-
apy available. The most commonly used drugs, such as
paromomycin and azithromycin or nitazoxanide, are only
eﬀective in combination with immune restoring agents [16].
Immunocompetent adult mice are capable of controling
Cryptosporidium parvum infections, while IFN-γ knockout
and severe combined immuno deﬁciency mice (SCID) are
susceptible to this parasite [17, 18]. Besides immunity, the
intestinal ﬂora can also inﬂuence resistance to Cryptosporid-
ium [19]: germ-free adult immunocompetent mice have an
increased susceptibility to Cryptosporidium whereas SCID
mice, colonized with a deﬁned anaerobic ﬂora (Altered
Schaedler Flora), are able to resist infection [20].
Beneﬁcial eﬀects of probiotics upon cryptosporidio-
sis have been demonstrated: adult mice (female C57BL/6
immunosuppressedbythemurineleukemiavirus(strainLP-
BM5), 3-4 weeks old) fed daily with L. reuteri strains 4000
and 4020 or L. acidophilus NCFM presented reduced oocyst
shedding [21, 22]. This partial protection was not associated
with an immune restoration (cytokines production). Daily
ingestion of L. reuteri was also eﬃcient to prevent C. parvum4 Journal of Parasitology Research
Table 1: List of probiotics tested on diﬀerent eukaryotic pathogens. The ﬁrst column illustrates the pathogens studied; the second one
indicates the probiotics tested (and if known, their strain reference; n.s. non speciﬁed) and the corresponding references. The third column
gives details of the level of the studies: clinical in patients (Human), in vivo in natural or experimental animal models (pig, mouse, calf, rat,
chicken, gerbil), or at a cellular level (cyst diﬀerentiation and survival, trophozoites development, and invasion capacity). The fourth column
speciﬁestheadministrationconditionsoftheprobiotic(A):a–d:beforeinfection;a—0–3days,b—3–7days,c—7–15days,d—morethan15
days, e—after infection, and f—concomitant administration and infection. The last column indicates the result (R)of the studies. Results are
indicated in terms of reduction of parasitic load in comparison to control for in vivo studies or in term of reduction of viability/infectivity
for in vitro assays, −:n e g a t i v ei m p a c to fp r o b i o t i c ,0 :n os i g n i ﬁ c a n te ﬀect, +: 25–50% of reduction, ++: 50–75% of reduction, and +++:
75–100% of reduction. n.d.: not determined; ∗: clinical case.
Pathogen Probiotic tested Host A R
Ascaris suum B. lactis (pig isolate) [53] Pig d n.d.
Babesia microti L. casei ATCC7469 [56, 58] Mouse a +++
b+
Cryptosporidium parvum
L. reuteri 4000, 4020 [21] Mouse c +++
L. reuteri 4000, 4020 or L. acidophilus NCFM [22] Mouse c ++
L. reuteri 4000, 4020 [23] Mouse c ++
L. rhamnosus GG + L. casei shirota [24] Human e ∗
VSL#3 or Actimel [25] Neonatal rat a 0
B. brevis, E. faecium, P. alcaligenes [26] Calf f 0
L. reuteri ATCC23272 or L. acidophilus NCFM [27, 28] Cell culture +
B. breve ATCC15698 or B. longum ATCC15707 [28] Cell culture +++
B. brevis, E. faecium and P. alcaligenes [29] Cell culture +++
Eimeria tenella/acervulina
Primalac [45–47] Chicken d ++
Mitomax [48] Chicken d +
Mitogrow [40] Chicken d +
L. acidophilus Lb33ac, L. salivarius Lb14c7 Lb16c6 [49] Cell culture ++
Giardia lamblia
L. johnsonii LA1 [33] Cell culture +++
L. johnsonii LA1 [34] Gerbil b ++
L. casei MTCC1423 [35] Mouse b +++
E. faecium SF68 [36, 37] Mouse b +++
Plasmodium chabaudi L. casei ATCC7469 [59] Mouse c +
Schistosoma mansoni Z. mobilis [55] Mouse b+ +
e −
Toxocara canis E. faecalis CECT7121 [52] Mouse b +++
Trichinella spiralis L. casei ATCC7469 [50, 51] Mouse b +
Trypanosoma cruzi L. casei ATCC7469 [60] Mouse b +++
B. breve: Biﬁdobacterium breve; B. brevis: Bacillus brevis; B. lactis: Biﬁdobacterium lactis; E. faecium: Enterococcus faecium; L. acidophilus: Lactobacillus
acidophilus; L. casei : Lactobacillus casei; L. johnsonii: Lactobacillus johnsonii; L. paracasei: Lactobacillus paracasei; L. reuteri: Lactobacillus reuteri; L. rhamnosus:
Lactobacillus rhamnosus; P. alcaligenes: Pseudomonas alcaligenes; S. boulardii: Saccharomyces boulardii; Z. mobilis: Zymomonas mobilis.
Sources of commercial probiotics: Actimel : Lactobacillus bulgaricus, Streptococcus thermophilius, and Lactobacillus casei DN-114 01; Mitogrow Imagilin
Technology,consistsoflivePediococcusacidilactici;Mitomax ImagilinTechnology,consistsoflivePediococcusacidilacticiandSaccharomycesboulardii;Primalac
containsprimarilyLactobacillusacidophilusandLactobacilluscasei;VSL#3:fourstrainsoflactobacilli(Lactobacillusplantarum,Lactobacilluscasei,Lactobacillus
acidophilus,andLactobacillusbulgaricus),threestrainsofbiﬁdobacteria(Biﬁdobacteriuminfantis,Biﬁdobacteriumlongum,andBiﬁdobacteriumbreve),andone
strain of streptococcus (Streptococcus thermophilius).
intestine colonization and tissue lesions in a host with a
deﬁcient immune system (gnotobiotic TCR-alpha deﬁcient
mice). Waters et al. suggested that protection was due
to secretion of as yet unidentiﬁed antimicrobial products
[23]. In human, a single case of resolution of prolonged
cryptosporidiosis by a probiotic treatment was documented
[24].
On the other hand, probiotics seem less eﬃcient in
neonatal animals [25]. No signiﬁcant beneﬁt could be
observed using two diﬀerent mixtures of probiotics, Actimel
or VSL#3 probiotic mixture, although there was a tendency
to a shorter duration of infection in probiotic-fed animals.
Nevertheless, the authors concluded that one could not rule
out some eﬀect in other experimental conditions, such as
a prolonged administration before infection and the use
of alternative animal models with a mature gut ﬂora and
immune system. An absence of eﬀect was also observed
under ﬁeld conditions in Holstein calves, born on a dairy
farm where cryptosporidiosis was endemic. In spite of a
daily ingestion of a bacterial mixture for 10 days after birth,Journal of Parasitology Research 5
the incidence of diarrhea and faecal shedding was similar in
treated and nontreated animals [26]. One of the limitations
of studies in farm animals is the simultaneous exposure to
both probiotic and parasite from birth onwards.
Interestingly,invitrostudiesdemonstratedtheinhibitory
eﬀects of cell-free supernatants of L. acidophilus NCFM and
L. reuteri strain 23272 on C. parvum and C. hominis viability
and infectivity [27, 28]. Similarly, cell-free supernatants
of Bacillus brevis, Enterococcus faecium,a n dPseudomonas
alcaligenes reduce C. parvum oocyst persistence by inducing
oocyst premature excystation [29]. The compounds at the
basis of such an inhibition are under investigation.
3.Giardia
Giardia lamblia (also known as Giardia intestinalis or
Giardia duodenalis) is an intestinal pathogenic protozoan
parasite belonging to the Diplomonad group, that causes
∼280 million symptomatic human infections per year [30].
This monoxenous waterborne parasite has the capacity
to infect a wide range of hosts. In humans, as little as
ten environmentally resistant cysts are suﬃcient to initiate
an infection. The cysts liberate the motile and replicative
forms known as trophozo¨ ıtes during their gastrointestinal
transit. These forms proliferate in the gut lumen, where
they adhere to the epithelium (Figure 2). This phase is
associatedwiththesymptomsofthedisease:waterydiarrhea,
epigastric pain, nausea, vomiting, and weight loss usually
appear 6–15 days after cyst ingestion, but half of the
infections remain asymptomatic. Treatments are based on
metronidazole and nitroimidazole, but infections may also
resolve spontaneously. T cells, neutrophiles, macrophages as
well as IgM, IgG, and IgA antibodies are major players of
the immune response necessary for resolution of giardiasis.
T-cell cytokines may also induce production and release of
antigiardial defensins [31]. Some factors, such as common
variable immunodeﬁciency (hypogammaglobulinemy) or
altered gut microﬂora, appear to predispose to Giardia infec-
tion [29]. Although the clinical impact has been reported
to be stronger in young children and undernourished or
immunodeﬁcient individuals, there is little insight into how
Giardia spp. cause the disease since the trophozoites are not
invasive and secrete unknown toxins [30].
The ﬁrst proposal of the use of probiotics to control
infections by Giardia came from the discovery that isogenic
mice presented a variable susceptibility to Giardia infection
depending on their intestinal ﬂora [32]. Interestingly, resis-
tance to Giardia infection could be transmitted from mouse
to mouse by common housing and was abrogated by using
antibiotics, such as neomycin, active against the resident
anaerobic ﬂora.
An important step towards the comprehension of the
probiotic activity was the discovery that the culture super-
natant of the probiotic strain LA1 of Lactobacillus johnsonii
was capable of controlling G. lamblia growth in vitro [33]. In
thisstudy,sixotherLactobacillusacidophilusstrainswerealso
tested but did not show any noticeable eﬀects. L. johnsonii
LA1 supernatant blocked G. lamblia development in G1
phase but was apparently unable to prevent the adhesion
of G. lamblia to epithelial cells. Biochemical characteriza-
tion of supernatants revealed the presence of unidentiﬁed
heat-sensitive low molecular weight product(s) [33]. Daily
addition of live bacteria to the drinking water of gerbils,
sev enda ysbefor eoralinfectionb yG.lambliacysts,protected
the animals [34]. A decrease in the production of cysts in
the faeces, a reduction of the prepatent phase and global
better health were also observed. This treatment showed
protection against the diminished nutrient absorption as
well as the histological changes of the intestinal mucosa
normally associated with giardiasis. Increased splenocyte
responses to T-cell and B-cell mitogens, as well as to Giardia
antigens, suggested that, in addition to a potential eﬀect of
extracellular factors, L. johnsonii LA1 treatment reinforced
the host immune response against Giardia.
Lactobacillus casei MTCC 1423 strain as well as Entero-
coccus faecium SF68 were also eﬀective in eliminating Giardia
infection from mice [35, 36]. Protection was associated with
a diminution of atrophied villi and inﬁltrating cells in the
small intestine of probiotic-treated mice [35]o rw i t ha n
enhancement of the immune response since a production
of speciﬁc anti-Giardia intestinal IgA and IgG was noticed
in treated mice [36]. Recently, in vivo experimentation on
malnourished mice showed that daily pretreatment with L.
casei MTCC1423 eﬃciently reduced both the severity and
the duration of giardiasis, compared to nonprobiotic-fed
malnourished mice [37].
Studies performed in human patients in 1995 indicated
the beneﬁcial eﬀect of the administration of the probiotic
yeastSaccharomycesboulardii(Reﬂos),notdirectlytoprevent
giardiasis but to help in the recovery from postinfection
irritable bowel syndrome (PI-IBS, see Section 7), a compli-
cation appearing in some patients cured from the parasite
by drug treatments [38]. This observation was supported by
a later study showing that S. boulardii reduced the number
of parasite cysts in faeces from patients treated by the
combination of S. boulardii and the drug metronidazole
versus patients treated by metronidazole only [39].
While these studies converge towards the existence of a
beneﬁcial eﬀect provided by diﬀerent types of probiotics in
giardiasis, additional work needs to be realized to determine
whether there is a direct eﬀect on G. lamblia development
in the host or just a reduction of the pathological eﬀects, or,
more likely, a combination of both.
4. Eimeria
Eimeria is an apicomplexan parasite responsible for coccid-
iosis in poultry, livestock, and small animals such as rabbits,
dogs, and cats. Avian coccidiosis is a major parasitic disease
in poultry, with a very high economical impact [40]. Birds
become infected through ingestion of sporulated oocysts
that subsequently excyst to form sporozoites in the lumen
of the upper intestine. These sporozoites migrate to their
preferred sites of development, diﬀerent between the seven
species of veterinary importance. They then invade villi
enterocytes and undergo a ﬁrst asexual multiplication, the6 Journal of Parasitology Research
schizogony, leading to the release of numerous merozoites
that initiate a second schizogony by infecting new epithelial
cells. Macro- and microgametes are ﬁnally produced, ini-
tiating the sexual phase that yields environmental resistant
oocysts that are shed in the faeces [41]( Figure 2). Drugs
(e.g., amprolium, halofuginone, or polyester ionophores
such as monensin lasalocid) and live vaccines are the two
main control measures to ﬁght this disease. However, drug
resistance has to be managed constantly, and no new drugs
have been introduced for many years. Live vaccines against
coccidiosis are highly eﬀective, based on nonattenuated and
attenuated strains. They show however a low margin of
safety for the former and a risk of reversion to virulence
as well as expensive large-scale production for the latter.
No successful approaches to develop recombinant vaccines
have been reported [42]. Alternative control methods are
therefore needed [43]. Probiotics have been widely used
in the poultry industry, because they help maintaining
the normal intestinal microﬂora, improve feed intake and
digestion, and are capable of stimulating the immune system
[44]. Only a limited number of studies have addressed their
protective eﬀect against the Eimeria species responsible for
avian coccidiosis [45–49].
TheadministrationofPrimalac,acommerciallyavailable
Lactobacillus-based preparation, to chicken from birth to
three weeks is able to stimulate intestinal intraepithelial
lymphocytes and signiﬁcantly decrease (up to 75% reduc-
tion) the number of E. acervulina oocysts in the treated
chickens[45].Moreover,inbirdsfedonavitaminAdeﬁcient
diet, Primalac was shown to enhance birds immunity, even
if, in this case, oocyst shedding was less reduced than
in the previous study (up to 26%) [46]. A third series
of experiments with the same general protocol but with
a doubled infective dose showed a small but signiﬁcant
elevation of cytokine levels (γ-IFN and IL-2) together with
a reduction in oocyst shedding in Primalac-treated versus
control chicken, but no diﬀerences in the anti-Eimeria
antibodylevel[47].Itwasconcludedthattheprotectionlevel
may depend upon the challenge dose but is mediated by
immune stimulation as attested by elevation of the cytokines
levels [47].
Other commercially available probiotic preparations
(Mitomax, a combination of Pediococcus acidilactici and
Saccharomyces boulardii,a n dM i t o g r o w ,Pediococcus acidi-
lactici only) were tested in chickens subsequently infected
with E. tenella and E. acervulina using the experimental
procedures described by Dalloul et al. [40, 48]. While
Mitomax caused a 10–38% reduction in the number of
shed oocysts, accompanied with an elevated level of anti-
Eimeria antibodies [48], Mitogrow caused an elevation of
anti-Eimeria antibodies and no signiﬁcant reduction in the
number of E. acervulina shed oocysts [40].
Thus,althoughtheresultsconvergetowardstheexistence
of a protective, though partial eﬀect, by these diﬀerent
probiotic preparations against avian coccidiosis, the mecha-
nisms involved remain currently elusive, with variable data
concerning the reduction in oocyst shedding, the levels of
cytokines, and anti-Eimeria antibodies.
Tierney et al. investigated the interactions between
chicken-derivedLactobacillusstrainsandEimeria[49].Three
Lactobacillus strains were isolated from diﬀerent parts of
chicken gastrointestinal tract and were tested for their capac-
ity to prevent E. tenella invasion in vitro in a MDBK (Madin-
Darby bovine kidney) cell model. All strains inhibited the
invasion signiﬁcantly, possibly through steric interference or
competitive exclusion. The potential eﬀect of their secreted
extracellular factors was further investigated by testing Lac-
tobacillus culture supernatants. One supernatant produced
by the caecum-derived isolate Lactobacillus salivarius Lb16c6
displayed a signiﬁcant activity that was marginally aﬀected
by a 30min treatment at 100◦C. The molecular principle
responsible for this inhibitory eﬀect is, however, not yet
discovered.
5. Worms
In the course of their work showing that immunostim-
ulants can induce nonspeciﬁc resistance against parasites,
Bautista-Garﬁas et al. evaluated the capacity of viable or
dead probiotic Lactobacillus casei to induce resistance against
Trichinella spiralis in mice [50]. This nematode is responsible
for trichinellosis, one of the most widespread and clinically
important diseases in the world. Humans can be infected
by eating infected food. Worms mature in the intestine
of an intermediate host, such as pig, enter the blood
and the lymphatic system and encyst in striated muscles.
The migration of larvae causes host tissue damages and
inﬂammatory reactions with complications, which may lead
to death. The eﬃciency of treatments based on mebendazole
or albendazole is variable. Both viable and dead L. casei
ATCC7469 were administrated orally to NIH mice and
induced a protective response with a signiﬁcant reduction of
bothadultworms(58and44%,resp.)andlarvaepergramof
muscle (up to 70%). Treatment with culture supernatant of
L. casei w a sl e s se ﬃcient but still showed a signiﬁcant eﬀect
(32% reduction of adult worms). The authors attribute the
protective eﬀect to the production of IL-2, γ-IFN, and nitric
oxide [50, 51].
Toxocara canis is an intestinal ascarid that infects pri-
marily dogs. Humans and rodents are paratenic hosts that
become infected by ingesting eggs, either on contaminated
f o o do rb yg e o p h a g y .I n g e s t e de g g sh a t c ha n ds p r e a do u t
throughout the body, leading to symptoms associated with
human toxocariasis (visceral or occular larva migrans or
covert toxocariasis). Basualdo et al. reported the spectacular
eﬀectofE.faecalisCECT7121onT. canis larvaedevelopment
in N:NIH-Swiss mice: a 90% reduction of the number of
larvae in liver and lungs was measured 48h after infection
with embryonated eggs [52].
Similarly, Ascaris suum, which normally infects pigs,
can also be transmitted to humans, where the migrating
larvae produce liver lesions and eosinophilic pneumonitis.
Probiotic treatment of sows during pregnancy and of their
piglets after birth with Biﬁdobacterium lactis (a pig isolate)
attenuate the inhibition of glucose absorption in the small
intestine induced by A. suum infection, a sign associatedJournal of Parasitology Research 7
withtheparasiteexpulsionfromthejejunum[53].Probiotic-
treatedpigsstillexpulseA.suumnormallyfromtheintestine.
Treatment appears thus to counteract a negative aspect of
the response to infection related to nutrient uptake without
aﬀecting the protective immune response [53, 54].
Schistosoma mansoni, a blood-dwelling trematode worm,
is the primary causative agent of bilharziosis. Human infec-
tion is initiated during water exposure to the free-swimming
fork-tailedcercariae.Aftermaturationinskin,larvaemigrate
through the skin, blood, lungs, and liver and ﬁnally reach
the mesenteric venous plexus. Some of the eggs deposited
by the female adults pass through the venule walls, cross the
intestinal mucosa, and are evacuated with the fecal material.
Eggs then infect their intermediate snail host, Biomphalaria
glabrata. Zymomonas mobilis, a bacterium mainly known for
its bioethanol-producing capabilities and originally isolated
from alcoholic beverages, was reported to provide over 60%
protection from the infection of S. mansoni,i nm i c e ,w h e n
orally administrated as a curative treatment (7 days after
infection with cercaria) [55] .T h ed e g r e eo fp r o t e c t i o nw a s
determined 60 days after infection, by the number of worms
recovered from the murine liver by perfusion. As far as
histopathology was concerned, lesions (granulomas) in the
liver and the intestine were numerous and similar in the
treated and nontreated groups. Eggs were also abundant in
the intestine, particularly in the jejunum-ileum part. On the
contrary, the administration of Z. mobilis as a prophylactic
way (7 days before infestation) did not signiﬁcantly protect
from infection, and worse, the combination of prophylactic
and curative treatments exacerbated the symptoms.
6.Other Parasites
For other eukaryotic pathogens, the eﬀects of probiotics
have mainly been reported by one research group that
demonstrated the potential eﬀect of L. casei ATCC 7469
in the protection of nongut parasites, such as Babesia,
Plasmodium,o rTrypanosoma (Bautista and coworkers in
Mexico).
Oral or intraperitoneal treatments of L. casei ATCC 7469
in Babesia microti (Gray strain) infected mice signiﬁcantly
reducedparasitemia,potentiallythroughastimulationofthe
innate immune system [56] .T h ep r o t e c t i v er e s p o n s ew a s
improved when the lactobacilli were administered 3 days
before or on the same day of parasite infection versus 7 days
before. Since in B. bovis infections, the early innate response
has been attributed to early appearance of IL-12 and γ-IFN
transcripts in the spleen [57], it has been suggested that
L. casei could enhance this protective response. The molec-
ular mechanism is currently under investigation, through
the testing of low and high molecular components isolated
from lactobacilli for their capacity to induce early protective
immune response against B. microti [58].
L. casei ATCC 7469 also conferred a protective eﬀect
against the malaria parasite Plasmodium chabaudi AS in
NIH mice [59]. L. casei enhanced a nonspeciﬁc resistance
to P. chabaudi, with longer prepatent periods (5 days versus
4 days in control mice), shorter patent periods (8 days
versus 11 days in control mice), accompanied by a reduction
in parasitemia and viability of parasites recovered from
the spleen of treated mice. Nitric oxide concentration was
increased (500% to 900%) in serum of L. casei-treated mice
and was proposed to confer a protective eﬀect upon the
plasmodial infection.
The same probiotic strain also showed a protective
eﬀect against Trypanosoma cruzi (Ninoa strain), the agent
of Chagas disease in NIH mice [60]. Oral or intraperitoneal
doses of lactobacilli 7 days before parasite infection showed
a signiﬁcantly reduced parasitemia over the next 50 days.
Whether the host immune response, known to be stimulated
by L. casei [61] and capable of controling T. cruzi infections
[62], was responsible for this protective eﬀect is still dis-
cussed.
Finally, a beneﬁcial eﬀect of administration of the
probiotic yeast Saccharomyces boulardii (Ultra-levure) in
association with antibiotics was reported in acute amoebiasis
due to Entamoeba histolytica, with signiﬁcant decrease of the
duration of symptoms (diarrhea, fever, abdominal pain) and
presence of cysts in stools [63].
7. PostinfectiveIrritableBowel Syndrome
Irritable bowel syndrome (IBS) is a functional gastrointesti-
nal disorder in which abdominal pain is associated with
defecation or alterations in bowel habits in the absence
of an organic cause [64]. The pathophysiology of IBS
remains elusive but it is generally accepted that symptoms
originate from a gut dysfunction and include altered motility
in response to stimuli and sensory perception [65, 66].
Low-grade inﬂammation and immune activation are one
proposed mechanism of IBS pathogenesis. The strongest
recognized environmental risk factor for IBS development is
bacterial gastroenteritis. Postinfective IBS (PI-IBS) patients
display similar dysfunctions to those of IBS patients. As
gastroenteritis disrupts intestinal microbiota, it has been
proposed that correction of gut dysfunctions by commen-
sal microbiota could oﬀer therapeutic potential in PI-IBS
patients [65, 67, 68]. Intestinal parasites, such as Blastocystis
hominis, Cryptosporidium parvum, Giardia lamblia, Enta-
moeba histolytica, or the nematode Trichinella spiralis can
cause IBS-like symptoms and may also play a possible role
in the IBS etiology [66, 69, 70]. The potential of probi-
otics to treat IBS-like symptoms associated with parasite
infection has been little evaluated. Reliable studies come
from the T. spiralis model in NIH Swiss mice, which shows
similarities to PI-IBS [65]. Adult worms and larvae induce
functional alterations (inﬂammatory response, increased
bowel motility, growth of smooth muscle, and modiﬁcation
of mucus production), which persist at least 3 weeks after
parasite expulsion. None of the tested probiotics adminis-
trated orally (Lactobacillus paracasei NCC2461, L. johnsonii
NCC533 (LA1), Biﬁdobacterium longum NCC2705, and
B. lactisNCC362)interferedwithparasiteeviction.However,
as t r a i ns p e c i ﬁ ce ﬀect was measured on the persistent muscle
hypercontractibility observed in this model after recovery
from infection: only L. paracasei attenuates postinfective8 Journal of Parasitology Research
hypercontractibility. The beneﬁcial eﬀect is correlated with
a modulation of the immunologic response to the parasite
and/or a direct or indirect eﬀect of L. paracasei on muscle
hypercontractibility. The protective activity is also present in
L. paracasei-culture supernatant and is heat labile, indicating
that it is probably a secreted metabolite. L. paracasei eﬀects
were further investigated using an elegant NMR-based
metabolomicapproach[71].T.spiralis-infectedmiceshowed
altered metabolic proﬁles, which were related to intestinal
hypercontractibility, muscular hypertrophy, and disrupted
jejunal functions. L. paracasei treatment normalized the
muscular activity and the disturbed energy metabolism.
The authors concluded that L. paracasei treatment may be
beneﬁcial in patients with PI-IBS.
In a gnotobiotic T-Cell receptor-deﬁcient mice model,
C. parvum induces a persistent infection as well as IBS-
like lesions in the caecum. When these mice were pre-
colonized by L. reuteri and then challenged with C. parvum,
fewer parasites were detected, and associated hyperplasic and
inﬂammatory lesions were diminished [23, 70].
Although clinical evidences of eﬃcacy begin to emerge,
the overall impact of probiotics for PI-IBS treatments stays
highly debated. This is mainly due to the diﬃculty to
compare the studies because of diﬀerences in experiment
design, probiotic dose and strains, and responsible agent
[67, 68, 72–74].
8. ProbioticTreatments, anEmerging
Therapeutic Strategy inParasiticDiseases?
The above studies converge towards a beneﬁcial eﬀect of
probiotics to control parasitic infections and point towards
a strain-speciﬁc probiotic eﬀect. As yet, little is known on the
cellular or molecular mechanisms sustaining these eﬀects. So
far, the experimental studies on Cryptosporidium, Giardia,o r
Eimeria are the only ones that support a probiotic action
via the secretion of an active principle that can inhibit
parasitedevelopment,althoughthemolecularnatureofthese
components remains unknown. Probiotics have been also
proposed to inﬂuence gut microﬂora and development of
immune response. The underlying mechanisms are however
not clear, involving stimulation of diﬀerent subsets of
immune system cells to produce cytokines, which in turn
play a role in the induction and regulation of the immune
response, and to enhance intestinal IgA immune responses
and increase intestinal mucin production (for a review, see
[75]). L. johnsonii LA1, Lactobacillus strain GG, or Biﬁdobac-
terium lactis Bb12 have all been shown to modulate IgA
immune responses [75], whereas L. rhamnosus GG increased
intestinal mucin production [76]. These actions may boost
intestinal clearance of parasites such as Giardia and could
explain the in vivo protection conferred by some probiotics
[31]. Similarly, IL-10 and secretory IgA response, impor-
tant actors in an eﬃcient anti-Cryptosporidium immune
response, have been shown to be induced by some pro-
biotic strains [77]. Even if a direct link between probiotic
administration, immune eﬀectors induction, and parasite
elimination has not been yet clearly established, it seems
highly probable.
Proposing probiotics as alternatives to classical treat-
ments, such as drugs or vaccines, against parasites appears
unreasonable; a complementary therapeutic approach to
reduce risks of infestation or to sustain classical treatments
seems more realistic. For the moment, studies of probiotic
eﬀects on parasites are still in their infancy, and further
investigations are needed to move forward in this direction.
Several important points also need to be addressed.
T h ep r o b i o t i c su s e dh a v et ob ep r e c i s e l yc h a r a c t e r i z e da t
as t r a i nl e v e l .
Eﬀorts need to be made to standardize protocols in
each model (administration, dose, time, etc.). Absence of
probiotic eﬀect on cryptosporidiosis was indeed observed
for short probiotic pretreatments (2 days) or concomitant
contact with probiotic and pathogen [25, 26]i nc o n t r a s t
to longer pretreatments (13 days [21, 22]). But long-term
immune stimulation does not increase the eﬀect. In a
healthy subject, a great activation of the immune system
cannot be conveniently obtained, because constant antigen
stimulation could produce negative eﬀects on the host,
including autoimmunity [9].
More studies need to be realised, combining a larger
number of pathogens as well as their corresponding host/
animal models, with a greater variety of probiotics (either
individually or in combination).
Another factor of variability that has to be taken into
account is the gut microﬂora of the experimental animal
models. While it is obvious that the animal genetic back-
ground is important, the environmental factors, such as
hygiene conditions, feed quality, and stress, can also aﬀect
the established microﬂora, inﬂuencing the results of the
studies [78]. To overcome such intrinsic variations, models
with identical genetic background (inbred strain) and a
controlled microﬂora, which are subject to the same feeding,
are needed. Simpliﬁed models such as gnotobiotic animals
(mice with a deﬁned microﬂora) are invaluable tools for
exploring eﬀects of gut microorganisms as probiotics on
the host [5]. It would also be interesting to monitor the
establishment of the probiotics in the gut and its inﬂuence
on the established microﬂora.
In depth understanding of the molecular mechanisms
sustaining probiotic action is required to properly design
future probiotic treatments. As probiotics can kill pathogens
through secretion, inhibit their adhesion or invasion, inacti-
vate toxins, or compete for nutriments, most studies focused
on intestinal pathogens with the hypothesis of a local
probiotic eﬃciency. But in vivo studies on nongut pathogens
(Plasmodium, Trypanosoma, Babesia,e t c . )s u p p o r tar e m o t e
eﬀect provided by probiotics probably through a nonspeciﬁc
immune stimulation. In all cases, a lot of eﬀort needs to go
in the elucidation of the mode of action of the promising
organisms.
9. Conclusion
The concept that probiotics could control the develop-
ment of eukaryotic pathogens is emerging. TherapeuticJournal of Parasitology Research 9
approaches with probiotics could help to reduce the risks of
infestation by speciﬁc parasites or complement classical anti-
parasite treatments. A better understanding of molecular
mechanisms underlying the beneﬁcial eﬀects of probiotic on
the parasite infection is essential to validate the approach.
Further deeper investigations are thus needed using more
deﬁned protocols (speciﬁc probiotics and experimental
models), as well as extended clinical investigations. Gnoto-
biotics, whose genotype and microbial status can be clearly
deﬁned and whose diet and environmental conditions can
be easily controlled, could be invaluable tools to go forward
in this direction.
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